Liver tests are irrelevant when prescribing statins

The Lancet

Volumn 376, Issue 9756, 2010, Pages 1882-1883

  Bader, Ted ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FATTY LIVER; HEALTH CARE COST; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; NONALCOHOLIC FATTY LIVER; NOTE; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 78649824344     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62142-3     Document Type: Note

References (5)

1. VG Athyros, K Tziomalos, TD Gossios for the GREACE Study Collaborative Group Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 2010 10.1016/S0140-6736(10)61272-X published online Nov 24.
2. T Bader, J Fazili, M Madhoun Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 2008 1383 1389
3. MF Madhoun, T Bader Statins improve ALT values in chronic hepatitis C patients with abnormal values Dig Dis Sci 55 2010 870 871
4. T Bader The myth of statin-induced hepatotoxicity Am J Gastroenterol 105 2010 978 980
5. FS Rzouq, ML Volk, HH Hatoum, SK Talluri, RR Mummadi, GK Sood Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians Am J Med Sci 340 2010 89 93